Heartflow, Inc. Common Stock logo

Heartflow, Inc. Common Stock(HTFL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 63 days
PROFIT SINCE LAST BUY
+7.14% ▲
LAST CLOSE
$48.46
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for HTFL

11/13/2026: HTFL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Heartflow, Inc. is a commercial-stage medical technology company that provides AI-driven, non-invasive software solutions for diagnosing and managing coronary artery disease. The company's primary business strength lies in its proprietary Heartflow One platform, which leverages computational fluid dynamics and robust clinical validation to reduce unnecessary invasive procedures. Its main growth opportunity centers on expanding insurance reimbursement and scaling hospital adoption of its advanced diagnostic tools globally. Key risks include ongoing net losses, valuation sensitivity, and execution challenges in hospital sales cycles. HTFL is best suited for growth-oriented investors willing to monitor commercial execution, clinical trial outcomes, and ongoing reimbursement progress.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company features rapid, high-double-digit revenue growth and an expanding total addressable market in healthcare AI.
Momentum investorStrong fit while signal remains positiveStock price momentum and frequent positive clinical catalysts attract active market participants.
Value investorWeak fitHeartflow remains unprofitable on a GAAP basis and trades at high growth-adjusted multiples.
Dividend investorWeak fitThe company pays no dividends and reinvests all cash flows into commercial scaling.
Low-risk investorWeak fitHigh share price volatility and ongoing net losses create elevated risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences significant price swings typical of commercial-stage medical technology equities.
Valuation riskMedium / highHigh expectations are baked into the valuation, leaving little room for operational execution misses.
Competition risk (AI and medical device competition)MediumThe company faces ongoing competition from established cardiovascular device makers and emerging AI diagnostics.
Business qualityStrongHeartflow possesses strong proprietary technology and robust clinical validation supporting its SaaS platform.
Dividend incomeLow / noneNo dividend is paid, making it unsuitable for income-seeking investors.
Execution riskMedium / highFuture success depends heavily on scaling hospital sales channels and securing broader global reimbursement.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.26B USD
Price to earnings Ratio 72.33
1Y Target Price 63.12
Price to earnings Ratio 72.33
1Y Target Price 63.12
Volume (30-day avg) 1.8M shares
Beta -
52 Weeks Range 20.13 - 60.66
Updated Date 11/15/2026
52 Weeks Range 20.13 - 60.66
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.67

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -29.98%
Avg. Invested days 32
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
HTFL receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
HTFL has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+39.9%) is partially offset by negative earnings growth (-21.1%), weak cash generation (FCF margin -33.5%), weak profitability (net margin -66.3%).

Financial Health Rating

★★★★★
HTFL's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 49.5%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is HTFL's strongest growth driver at +39.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+19.5%, solid) is also solid, while earnings growth (-21.1%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 99.7% and approximately 77.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.70% supports management-shareholder alignment.

Top 5 Institutional Investors

Bain Capital Life Sciences Investors, LLC 9.61%
Wellington Management Company LLP 8.95%
BlackRock Inc 5.91%
FMR Inc 5.49%
Vanguard Portfolio Management, LLC 4.08%

Unit Economics (Per $1K Revenue)

★★★★★
HTFL generates approximately $768 of gross profit, $-364 of operating income, and $-335 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.07%

Quantitative Style Profile

★★★★★
HTFL has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Heartflow One Software Platform ServicesPer-test analysis fees and service agreements for FFRct, Roadmap, and Plaque Analysis software utilized by hospitals and imaging centers.The company generates core revenue each time a medical facility uses its cloud-based software to analyze a patient's cardiac CT scan.
Global Commercial OperationsDirect sales and distribution across domestic and international healthcare markets.International expansion provides secondary revenue streams alongside its core U.S. hospital customer base.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 72.33
Forward PE -
Enterprise Value 4.12B
Price to Sales(TTM) 17.85
Enterprise Value 4.12B
Price to Sales(TTM) 17.85
Enterprise Value to Revenue 17.24
Enterprise Value to EBITDA -
Shares Outstanding 87.89M
Shares Floating 68.01M
Shares Outstanding 87.89M
Shares Floating 68.01M
Percent Insiders 5.7
Percent Institutions 99.65

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.